Appendix D. Evidence Tables

**Table D-1. Characteristics of included randomized trials**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Akuchekian et al., 20041  Iran | Randomized: 67 G1: 34 G2: 33 Analyzed:67 G1: 34 G2: 33 | Iranian Veterans Administration medical center  12 wks | CAPS  Baseline & Posttreatment | NR |
| Asukai et al., 20102  Japan | Randomized: 24 G1: 12 G2: 12 Post-treatment Analyzed: 24 G1: 12 G2:12 | Referred by psychiatric clinics or victim-support services; web recruitment - Outpatient  8 to 15 weekly sessionsa | CAPS  Baseline, Posttreatment, 3 mths, 6mths, 12 mths | Government |
| Bartzokis et al., 20053  United States | Randomized:65 G1: 33 G2: 32 Analyzed: 48 G1: 22 G2: 26 | VA med center  16 wks | CAPS  Baseline & Posttreatment (4 wks residential phase & 16 wks outpatient phase) | Foundation/non-profit & Government |
| Basoglu et al., 20074  Turkey | Randomized: 31 G1: 16 G2: 15 Analyzed: Week 4: 30 G1: 15 G2: 15 Analyzed: Week 8: 31 G1: 16 G2: 15 | Outreach Mental Health Care Delivery Program  Single sessiona | CAPS  Baseline, 4 wks, 8 wks, 12 wks, 24 wks, 1yr | Foundation/non-profit |
| Becker et al., 20075  United States | Randomized:30  G1: Unclear  G2: Unclear  Analyzed: 28  G1: 18  G2: 10 | VA med center  8 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company & Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Blanchard et al., 20036  United States | Randomized: 98 G1: 37 G2: 36  G3: 25 Analyzed: 98 G1: 37 G2: 36  G3: 25 | Outpatient special MH  8 to12 wks | CAPS  Baseline, Posttreatment, 3 mths | Government |
| Boden et al., 20127  United States | Randomized: 117  G1: 59  G2: 58  Analyzed: 98  G1: 49  G2: 49 | VA med center | Addiction Severity Index (ASI)  Baseline, Posttreatment, 6 mths | Government |
| Brady et al., 20008  United States | Randomized: 187 G1: 94 G2: 93 Analyzed: 183 G1: 93 G2: 90 | Outpatient Psychiatric clinics in academic medical centers and clinical centers  12 wks | CAPS-2 & IES  Baseline & Posttreatment or at the discontinuation | Pharmaceutical company |
| Brady et al., 20059  United States | Randomized: 94 G1: 49 G2: 45 Analyzed: 94 G1: 49 G2: 45 | Community and Outpatient Substance Abuse Treatment Programs  12 wks | CAPS  Baseline & Posttreatment | Government |
| Bryant et al., 200310  Australia | Randomized: 58 G1: 20 G2: 20 G3: 18 Analyzed: 58 G1: 20 G2: 20 G3: 18 | Outpatient special MH  8 wks | CAPS  Baseline, Posttreatment, 6 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Bryant et al., 200811  Australia | Randomized: 118 G1: 31 G2: 28 G3: 31 G4: 28 Analyzed: 118 G1: 31 G2: 28 G3: 31 G4: 28 | Outpatient special MH  8 wks | CAPS  Baseline, Posttreatment, 6 mths | Government |
| Butterfield et al., 200112  United States | Randomized: 15 G1: 10 G2: 5 Analyzed: 15 G1: 10 G2: 5 | Military  10 wks | CAPS-2  Baseline & Posttreatment | Pharmaceutical company |
| Carlson et al., 199813  United States | Randomized: 35 G1: 10 G2: 13 G3: 12 Analyzed: 34 G1:10 G2:12 G3:12 | VA med center  6 wks | CAPS  Baseline, posttreatment, 3 mths, 9 mths | Government |
| Chard et al., 200514  United States | Randomized: 71 G1: 36 G2: 35 Analyzed: 55 G1: 28 G2: 27 | Community  17 wks | CAPS-SX  Baseline, Posttreatment, 3 mths, 1 yr | Government |
| Cloitre et al., 200215  United States | Randomized: 58 G1: 31 G2: 27 Analyzed:46 G1: 22 G2: 24 | Community  12 mths | PTSD Sx improvement  Baseline, Posttreatment, 3 mths, 9 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Cloitre et al., 201016  United States | Randomized: 104  G1: 33  G2: 38  G3: 33  Analyzed:104  G1: 33  G2: 38  G3: 33 | Outpatient special MH  16 wks | CAPS & PSS-SR  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Connor et al., 199917  Meltzer-Brody et al., 200018  United States | Randomized: 54 G1: 27 G2: 27  Analyzed: 53 G1: 27 G2: 26 | Community  12 wks | Duke Global Rating for PTSD  Baseline, Posttreatment or at the discontinuation if prior to week 12 | Government |
| Cook et al., 201019  United States | Randomized: 124 G1: 61 G2: 63 Analyzed: 101 G1: 45 G2: 56 | Outpatient special MH  6 wks | CAPS  Baseline, Posttreatment, 1 month, 3 mths, 6 mths | Government |
| Cottraux, 200820  France | Randomized: 60 G1: 31 G2: 29 Analyzed:60 G1:31 G2:29 | Outpatient special MH  16 wks | General Criterion of Improvement (i.e., score <35 on the post-traumatic checklist scale)  Baseline, Posttreatment, 1yr, 2 yrs | Government |
| Davidson et al., 200121  United States | Randomized: 208 G1: 100 G2: 108 Analyzed: 202 G1: 98 G2: 104 | Study Centers–Outpatient  12 wks | CAPS-2 & IES  Baseline & Posttreatment or week of discontinuation if before week 12 | Pharmaceutical company |
| Davidson et al., 200322  United States | Randomized: 29  G1: Unclear G2: Unclear Analyzed:26 G1: 17 G2: 9 | Outpatient special MH  8 wks | SPRINT  Baseline & Posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Davidson et al., 200623  United States | Randomized: 538 G1: NR G2: NR G3: NR Analyzed: 531 G1: 179 G2: 173 G3: 179 | Outpatient PC  12 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company |
| Davidson et al., 200624  Argentina, Chile, Colombia, Denmark, Finland, Mexico, Norway, Portugal, South Africa, Spain, Sweden, and United Kingdom | Randomized: 329 G1: 161 G2: 168 Analyzed: 329 G1: 161 G2: 168 | Outpatient PC  24 wks | CAPS-SX  Baseline and posttreatment or at the time of discontinuation if before week 24 | Pharmaceutical company |
| Davidson et al., 200725  United States | Randomized: 232 G1: 116 G2: 116 Analyzed: 202 G1: 105 G2: 97 | Outpatient special MH  12 wks | CAPS, DTS & TOP-8  Baseline & Posttreatment | Pharmaceutical company |
| Davis et al., 200826  United States | Randomized: 85 G1: 44 G2: 41 Analyzed: G1:41 G2:41 | VA med center  8 wks | CAPS  Baseline & Posttreatment | Government |
| Ehlers et al., 200327  United Kingdom | Randomized: 85 G1: 28 G2: 28 G3: 29 Analyzed:78 G1: 28 G2: 25 G3: 25 | Outpatient special MH  Mean: 9 wks; 0-3 booster sessions | CAPS & PDS  Baseline, Posttreatment, 3 mths, 6 mths, 9 mths | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Ehlers et al., 200528  United Kingdom | Randomized: 28 G1: 14 G2: 14 Analyzed: 28 G1: 14 G2: 14 | Outpatient PC  4 to 12 wks and up to 3 monthly booster sessions | CAPS  Baseline, Posttreatment, 6 mths | Foundation/non-profit |
| Fecteau et al., 199929  Canada | Randomized: 23 G1: 12 G2: 11 Analyzed: 20 G1: 10 G2: 10 | Outpatient special MH  4 wks | CAPS-2,  Baseline, Posttreatment, 3 mths, 6 mths | Foundation/non-profit |
| Foa et al., 199930  Zoellner et al., 199931  United States | Randomized: 96 G1: 25 G2: 26 G3: 30  G4: 15 Analyzed: 79 G1: 23 G2: 19 G3: 22 G4: 15 | NR  9 wks | PSS-I  Baseline, Posttreatment, 3 mths, 6 mths, 12 mths | Government |
| Foa et al., 200532  United States | Randomized: 190 G1: NR  G2: NR G3: NR Analyzed: 179 G1: 79 G2: 74 G3: 26 | Community and Academic Specialty Clinic  12 wks (9-12 sessions, 1 session per week) | PSS-I  Baseline, Posttreatment, 3 mths, 6 mths, 12 mths | Government |
| Forbes et al., 201233  Australia | Randomized: 59  G1: 30  G2: 29  Analyzed:59  G1: 30  G2:29 | Veterans and Veterans Families Counseling Service  12 wks | CAPS  Baseline, Posttreatment, 3 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Ford et al., 201134  United States | Randomized:146  G1: 48  G2: 53  G3: 45  Analyzed: 146  G1: 48  G2: 53  G3: 45 | Community  12 sessionsa | CAPS  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Friedman et al., 200735  United States | Randomized: 169 G1: 86 G2: 83 Analyzed:166 G1: 84 G2: 82 | VA med center  12 wks | CAPS-2  Baseline & Posttreatment | Pharmaceutical company |
| Gamito et al., 201036  Portugal | Randomized: 10 G1: 5 G2: 2 G3: 3 Analyzed:9 G1: 4 G2: 2 G3: 3 | Military  12 Sessionsa | CAPS  Baseline & Posttreatment | Government |
| Gersons et al., 200037  Netherlands | Randomized: 42 G1: 22 G2: 20 Analyzed: 42 G1: 22 G2:20 | Referred by occupational physicians, police department  16 wks | SI-PTSD & SCL-90  Baseline, Posttreatment, 3 mths | Government |
| Hamner et al., 200338  United States | Randomized:40 G1: 20 G2: 20 Analyzed: 37 G1: 19 G2: 18 | Military  5 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Hien et al., 200439  United States | Randomized:128 G1: Unclear G2: Unclear G3: 32 (non-random) Analyzed: 107 G1: 41 G2: 34 G3: 32 | Community  12 wks | CAPS & IES  Baseline, Posttreatment, 6 mths, 9 mths follow-up | Government |
| Hien et al., 200940  Hien et al., 201241  United States | Randomized: 353 G1: 176 G2: 177 Analyzed:289 G1: 140 G2: 149 | Community  6 wks | CAPS  Baseline & Posttreatment | Government |
| Hinton et al., 200542  United States | Randomized: 40 G1: 20 G2: 20 Analyzed: 40 G1: 20 G2: 20 | Outpatient special MH  12 wks | CAPS  Baseline, Posttreatment, 12 wks after the completion of therapy | NR |
| Hinton et al., 200943  United States | Randomized: 24 G1: 12 G2: 12 Analyzed:24 G1: 12 G2: 12 | Community  12 wks | CAPS  Baseline & Posttreatment | NR, but at least 1 author has pharmaceutical affiliation |
| Hinton et al., 201144  United States | Randomized: 24 G1: 12 G2: 12 Analyzed: 24 G1: 12 G2: 12 | Community  14 wks | PTSD checklist  Baseline, Posttreatment, 12 wks | Government |
| Hogberg et al., 200745  Sweden | Randomized: 24 G1: 13 G2: 11 Analyzed: 21 G1: 12 G2: 9 | Employees of the public transportation system - Outpatient  2 mths | PTSD dx  Mean 10 days after treatment (last month of study) | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Hollifield et al., 200746  United States | Randomized: 84 G1: 29 G2: 28  G3: 27 Analyzed:73 G1: 24 G2: 25  G3: 24 | Outpatient special MH  12 wks | PSS-SR  Baseline, Posttreatment, 3 mths | Government |
| Johnson et al., 201147  United States | Randomized: 70 G1: 35 G2: 35 Analyzed: 70 G1: 35 G2: 35 | Community  8 mths | CAPS  Baseline & Posttreatment, 1 week, 3 mths, 6 mths | Government |
| Krakow et al., 200148  United States | Randomized: 186 G1: 88 G2: 80 Analyzed: 114 G1:54 G2:60 | Community  5 wks | PSS & CAPS  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Kruse et al., 200949  Germany | Randomized: 70 G1: 35 G2: 35 Analyzed:64 G1: 34 G2: 30 | Yugoslavian Refugees  3 month weekly sessions; after that once every 2 wks for a total of 25 hours of therapy | HTQ  Baseline, Posttreatment, 12 mths | Academic |
| Krystal et al., 201150  United States | Randomized: 296 G1: 147 G2: 149 Analyzed: 247 G1: 123 G2: 124 | VA med center  24 wks | CAPS  Baseline & Posttreatment | Government |
| Kubany et al., 200351  United States | Randomized: 37 G1: 19 G2: 18 Analyzed: 32 G1:18 G2:14 | NR  4.5 mths (7 to 10 sessions)) | PTSD remission  Baseline, Posttreatment, 3 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Kubany et al., 200452  United States | Randomized:125  G1: 63  G2: 62  Analyzed:125  G1: 63  G2: 62 | Community  4 to 5.5 wks | CAPS  Baseline, Posttreatment, 3 mths, 6mths | Government |
| Liedl et al., 201153  Germany & Switzerland | Randomized: 36 G1: 12 G2: 12 G3: 12 Analyzed:30 G1: 10 G2: 10 G3:10 | Outpatient special MH  Average treatment of 4.8 mths | PDS  Baseline & Posttreatment | NR |
| Lindauer et al., 200554  The Netherlands | Randomized: 24 G1: 12 G2: 12 Analyzed: 24 G1: 12 G2: 12 | Outpatient PC  16 wks | SI-PTSD  Baseline & Posttreatment | Government |
| Litz et al., 200755  United States | Randomized: 45 G1: 24 G2: 21 Analyzed: G1:23 G2:20 | Military  8 wks | PTSD Symptom Scale - Interview Version  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Marks et al., 199856  Lovell et al., 200157  England | Randomized: 87 G1: 23 G2: 19 G3: 24 G4: 21 Analyzed: 77 G1: 20 G2: 18 G3: 19 G4: 20 | Community  10 wks | CAPS-2, IES  Baseline, Posttreatment, 1 month, 3 mths, 6 mths | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Marshall et al., 200158  United States | Randomized: 563 G1: 188 G2: 187 G3: 188 Analyzed:551 G1: 183 G2: 182 G3: 186 | NR–Outpatient  12 wks | CAPS-2  Baseline & Posttreatment | Pharmaceutical company & Government |
| Martenyi et al., 200259  Martenyi et al., 200660  Belgium, Bosnia, Croatia, Yugoslavia Israel, & South Africa | Randomized: 301 G1: 226 G2: 75 Analyzed: 301 G1: 226 G2: 75  Subgroup Analysis: 144 G1: 110 G2: 34 | Other - Study Centers (Outpatient, but not clear)  12 wks | TOP-8  Baseline & Posttreatment | Pharmaceutical company |
| Martenyi et al., 200761  United States | Randomized:411 G1: 163 G2: 160 G3: 88 Analyzed:298 G1:114 G2:120 G3: 64 | Study Centers -Outpatient  12 wks | TOP-8  Baseline & Posttreatment | Pharmaceutical company |
| McDonagh et al., 200562  United States | Randomized: 74 G1: 29 G2: 22 G3: 23 Analyzed: 74 G1: 29 G2: 22 G3: 23 | NR  14 wks | CAPS  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Monnelly et al., 200363  United States | Randomized: 16 G1: 8 G2: 8 Analyzed:15 G1:7 G2:8 | VA med center  6 wks | PCL-M  Baseline & Posttreatment | Foundation/non-profit & Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Monson et al., 200664  United States | Randomized: 60 G1: 30 G2: 30 Analyzed: 60 G1: 30 G2: 30 | VA med center  12 sessions (twice weekly)a | CAPS  Baseline, Posttreatment, 1 month | Government |
| Mueser et al., 200865  United States | Randomized: 108 G1: 54 G2: 54 Analyzed: 59 G1: 32 G2: 27 | Outpatient special MH  12 to16 sessionsa | CAPS-Total  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Nacasch et al., 201166  Israel | Randomized:30  G1: 15  G2: 15  Analyzed:30  G1:15  G2:15 | VA med center  9 to 15 weeks | PSS-I  Baseline, Posttreatment, 12 mths | NR |
| Neuner et al., 200467  Uganda & Sudan | Randomized: 43 G1: 17 G2: 14 G3: 12 Analyzed: 43 G1: 17 G2: 14 G3: 12 | Sudanese Refugees in a Ugandan refugee settlement  3 to 4 wks | Posttraumatic Stress Diagnostic Scale  Baseline, Posttreatment, 4 mths, 1 yr | Foundation/non-profit |
| Neuner et al., 200868  Uganda | Randomized: 277 G1: 111 G2: 111 G3: 55 Analyzed: 277 G1: 111 G2: 111 G3: 55 | Rwandan and Somalian refuges in a Ugandan refugee settlement  3 wks | Posttraumatic Stress Diagnostic Scale  Baseline, Posttreatment, 6 mths | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Neuner et al., 201069  Germany | Randomized: 32 G1: 16 G2: 16 Analyzed:32 G1: 16 G2: 16 | Outpatient special MH  Sessions were scheduled on a weekly or bi-weekly basis, with a median of 9 treatment sessions. Treatment was terminated at the discretion of the therapist, with a range of 5 to 17 sessionsa | PDS  Baseline, Posttreatment, 6 mths | Foundation/non-profit |
| Nijdam et al., 201270  The Netherlands | Randomized:140  G1: 70  G2: 70  Analyzed: 140  G1:70  G2:70 | Outpat special MH  17 wks | IES-R  Baseline & Posttreatment | Academic |
| Panahi et al., 201171  Iran | Randomized:70  G1: 35  G2: 35  Analyzed:  G1: 35  G2:35 | Outpat special MH  10 wks | IES-R  Baseline & Posttreatment | Academic |
| Petrakis et al., 201172  United States | Randomized:88 G1: 22 G2: 20 G3: 22 G4: 24 Analyzed: 88 G1: 22 G2: 20 G3: 22 G4: 24 | Veterans from outpatient clinics and nonveterans outpatients from the community  12 wks | CAPS  Baseline & Posttreatment | Government |
| Raskind et al., 200373  United States | Randomized: 10 G1: 5 G2: 5 Analyzed:10 G1: 5 G2: 5 | VA med center  20 wks | CAPS “Recurrent Distressing Dreams Scale”  Baseline & Posttreatment | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Raskind et al., 200774  United States | Randomized: 40 G1: 20 G2: 20 Analyzed: 34 G1: 17 G2: 17 | VA med center  8 wks | CAPS "Recurrent Distressing Dreams & PSQI  Baseline & Posttreatment | Government |
| Reich et al., 200475  United States | Randomized: 21 G1: 12 G2: 9 Analyzed: 21 G1: 12 G2: 9 | Community  8 wks | CAPS-1 and CAPS-2  Both at baseline and at 1 wk, 2 wks, 4 wks, 8 wks; CAPS-1 readministered at 8 wks | Pharmaceutical company |
| Resick et al., 200276  Resick et al., 200377  Resick et al., 201278  United States | Randomized: 181 G1: NR G2: NR  G3: NR  Analyzed: 171 G1: 62 G2: 62  G3: 47  Avaliable for LTFU: 126  G1: 63  G2: 63 | NR  6 wks | CAPS  Baseline, posttreatment, 3 mths, 9 mths, 5 to 10 years | Government |
| Rothbaum et al., 199779  United States | Randomized: 21 G1: Unclear G2: Unclear Analyzed:18 G1: 10 G2: 8 | Outpatient special MH  4 wks | PSS  Baseline & Posttreatment | Academic |
| Rothbaum et al., 200580  United States | Randomized: 72 G1: 24 G2: 26 G3: 24 Analyzed:60 G1: 20 G2: 20 G3: 20 | Outpatient special MH  4.5 wks | CAPS  Baseline, posttreatment, 6 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Rothbaum et al., 200681  United States | Randomized: 65 G1: 34 G2: 31 Analyzed: 65 G1: 34 G2: 31 | Outpatient special MH  6 wks | SI-PTSD  Baseline & Posttreatment | Pharmaceutical company |
| Schneier et al., 201282  United States | Randomized: 37 G1: 19 G2: 18 Analyzed:37 G1:19 G2:18 | Outpatient special MH  10 wks | CAPS  Baseline & Posttreatment | Government |
| Schnurr et al., 200383  United States | Randomized: 360 G1: 180 G2: 180 Analyzed: 325 G1: 162 G2: 163 | VA med center  30 wks active treatment and 5 subsequent monthly booster sessions (12 mths total) | CAPS  Baseline, posttreatment, at the end of the booster sessions; 12 mths, 18 mths, 24 mths | Government |
| Schnurr et al., 200784  United States | Randomized: 284 G1: 141 G2: 143 Analyzed: 284 G1: 141 G2: 143 | VA med center  10 wks | CAPS  Baseline, posttreatment, 3 mths, 6 mths | Government |
| Schnyder et al., 201185  Switzerland | Randomized: 30 G1: 16 G2: 14 Analyzed: 30 G1: 16 G2: 14 | NR  16 wks | CAPS  Baseline, posttreatment, 6 mths | Foundation/non-profit & Academic |
| Simon et al., 200886  United States | Randomized: 25 G1: 11 G2: 14 Analyzed: 23 G1: 9 G2: 14 | Outpatient PC  10 wks | SPRINT  Baseline & posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Spence et al., 201187  Australia | Randomized: 44 G1: 23 G2: 21 Analyzed:42 G1: 23 G2:19 | Community  8 wks | PCL-C  Baseline, posttreatment, 3mths | Academic |
| Stein et al., 200288  United States | Randomized:19  G1: 10 G2: 9 Analyzed:19 G1: 10 G2: 9 | VA med center  8 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company |
| Tarrier et al., 199989  Tarrier et al., 199990  England | Randomized: 72 G1: 35 G2: 37 Analyzed : 62  G1: 29 G2: 33 | Referred from primary, secondary, & voluntary health services - Outpatient  16 sessions (over 112 days)a | CAPS, Penn Inventory, & IES  Baseline, Posttreatment, 6 mths, 12 mths | Foundation/non-profit |
| Taylor et al., 200391  Canada | Randomized:60 G1: 19 G2: 22  G3: 19 Analyzed:45 G1: 15 G2: 15  G3: 15 | Outpatient special MH  8 wks | CAPS  Baseline, Posttreatment, 1 month, 3 mths | Foundation/non-profit |
| Tucker et al., 200192  United States and Canada | Randomized: 323 G1: 163 G2: 160 Analyzed: 307 G1: 151 G2: 156 | Other–Outpatient  12 wks | CAPS-2  Baseline & Posttreatment | Pharmaceutical company |
| Tucker et al., 200393  Tucker et al., 200494  United States | Randomized: 59 G1: 25 G2: 23 G3: 10 Analyzed: 58 G1: unclear G2: unclear G3: unclear | Outpatient special MH  10 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Tucker et al., 200795  United States | Randomized: 40 G1: 20 G2: 20 Analyzed:38 G1: 19 G2: 19 | Outpatient special MH  12 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company |
| van der Kolk et al., 199496  United States | Randomized: 64 G1: 33 G2: 31 Analyzed: 47 G1: 21 G2: 27 | Hospital Trauma Clinic & VA Outpatient Clinic  5 wks | CAPS  Baseline & Posttreatment | Pharmaceutical company |
| van der Kolk et al., 200797  United States | Randomized: 88 G1: 29 G2: 30 G3: 29 Analyzed: 88 G1: 29 G2: 30 G3: 29 | Outpatient special MH  8 wks | CAPS  Baseline, Posttreatment, 6 mths | Government |
| van Emmerik et al., 200898  Netherlands | Randomized:125 G1: 41 G2: 44 G3:40 Analyzed:125 G1:41 G2:44 G3:40 | Outpatient special MH  5 sessions (Overall Mean 119.49 days)a | IES  Baseline, Posttreatment, follow-up time varied | Government |
| Yeh et al., 201199  Brazil | Randomized:35 G1: 17 G2: 18 Analyzed: 31 G1: 17 G2: 14 | Outpatient special MH  12 wks | CAPS  Baseline & Posttreatment | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Sizes | Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Zlotnick et al., 2009100  United States | Randomized: 49 G1: 27 G2: 22 Analyzed: 44 G1: 23 G2: 21 | Prison  6 to 8 wks | CAPS  Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Zohar et al., 2002101  Israel | Randomized: Unclear G1: NR G2: NR Analyzed: 42 G1: 23 G2: 19 | Military  10 wks | CAPS-2  Baseline & Posttreatment | Pharmaceutical company |

aNumber of treatment sessions reported when duration of treatment not specified

Abbreviations: CAPS = Clinician-Administered PTSD Scale; CAPS-1 = Clinician-Administered PTSD Scale, Version 1; CAPS-2 = Clinician-Administered PTSD Scale, Version 2; CAPS-SX = Clinician-Administered PTSD Scale; DTS = Davidson Trauma Scale; Dx = diagnosis; G = group; HTQ = Harvard Trauma Questionnaire; IES = Impact of Event Scale; MH = mental health; mths = months; NR = not reported; PC = patient center; PCL-C = Posttraumatic stress disorder checklist-civilian version; PCL-M = Posttraumatic stress disorder checklist-military version; PDS = Posttraumatic Stress Diagnostic Scale; PSQI = Pittsburgh Sleep Quality Index; PSS =PTSD Symptom Scale; PSS-I = PTSD Symptom Scale Interview; PSS-SR = PTSD Symptom Scale Self-report Version; Psych = psychiatric; PTSD = Posttraumatic Stress Disorder; SCL-90 = 90 item symptoms checklist; SI-PTSD = Structured Interview for PTSD; SPRINT = Short PTSD Rating Interview; Sx = serious; TOP-8 = Treatment-outcome posttraumatic; stress disorder scale (8 item); VA = Veterans Administration; wks = weeks; Yr = year.